Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
36.36
+0.08 (0.22%)
At close: Jul 24, 2026, 4:00 PM EDT
37.36
+1.00 (2.75%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Agios Pharmaceuticals Employees
As of December 31, 2025, Agios Pharmaceuticals had 540 total employees, including 539 full-time and 1 part-time employees. The number of employees increased by 52 or 10.66% compared to the previous year.
Employees
540
Change (1Y)
52
Growth (1Y)
10.66%
Revenue / Employee
$122,311
Profits / Employee
-$782,598
Market Cap
2.16B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 540 | 52 | 10.66% | 539 | 1 |
| Dec 31, 2024 | 488 | 102 | 26.42% | 486 | 2 |
| Dec 31, 2023 | 386 | -7 | -1.78% | 383 | 3 |
| Dec 31, 2022 | 393 | 1 | 0.26% | 389 | 4 |
| Dec 31, 2021 | 392 | -170 | -30.25% | 390 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| UroGen Pharma | 298 |
| Harmony Biosciences Holdings | 293 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Mesoblast | 81 |
| Sionna Therapeutics | 59 |
| Palvella Therapeutics | 29 |
AGIO News
- 5 days ago - Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright - TheFly
- 5 days ago - Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial - TheFly
- 5 days ago - Agios Pharmaceuticals announces topline results from tebapivat trial - TheFly
- 5 days ago - Agios Pharma to discontinue sickle cell disease treatment development - Reuters
- 5 days ago - Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - GlobeNewsWire
- 18 days ago - Agios Pharmaceuticals rises 13.5% - TheFly
- 18 days ago - Leerink sees Priority Review designation as positive sign for Agios’ mitapivat - TheFly
- 19 days ago - H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat - TheFly